Přihlásit se Zaregistrujte se zdarma

Vydané akcie společnosti Cotinga Pharmaceuticals

Jaká je hodnota metriky Vydané akcie společnosti Cotinga Pharmaceuticals?

Hodnota metriky Vydané akcie společnosti Cotinga Pharmaceuticals, Inc. je 21.986M

Jaká je definice metriky Vydané akcie?



Vydané akcie (Shares outstanding) je počet všech akcií společnosti nebo finančních aktiv, které byly autorizované, vydané a koupené investory a jsou jimi vlastněné.

Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.

Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.

Vydané akcie společností v sektoru Health Care sektor na TSXV ve srovnání se společností Cotinga Pharmaceuticals

Čemu se věnuje společnost Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.

Firmy s metrikou vydané akcie podobnou společnosti Cotinga Pharmaceuticals